The Federal Court has upheld Novartis’ appeal of a ruling revoking its patent for an oral form of multiple sclerosis drug Gilenya, after Australian generic drug maker Arrow Pharmaceuticals dropped its opposition to the patent despite prevailing before IP Australia.
Noni B owner fights ACMA bid for docs over potential Spam Act violations
AMP hits back at class action, says buy-out policy changes needed to avoid ‘BOLR run’
Delegate deflates Ann Taylor’s opposition to Nike’s ‘Aeroloft’ trade mark
Zip Co crushes Flexigroup’s ‘No Interest’ trade mark
Full Court gives Branhaven another shot at bovine gene patent
Lawyer settles case against firm accused of ‘workplace culture of sniping’
Merck Sharp & Dohme drops lawsuit over Januvia patent
Ernst & Young to be sued in class action over Slater & Gordon audits
Class members would get ‘diddly-squat’ in $1.9M Appco settlement, judge says
A judge has said further investigation into the financial position of Appco Group is needed before he can sign off on a $1.9M settlement in a $65 million sham contracting class action against the fundraising company, under which litigation funder Harbour would get a 50 per cent cut and group members would recover “diddly-squat”.